NASDAQ:ALT Altimmune Q3 2025 Earnings Report $4.00 +0.03 (+0.76%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$4.02 +0.02 (+0.50%) As of 08:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Altimmune EPS ResultsActual EPSN/AConsensus EPS -$0.29Beat/MissN/AOne Year Ago EPSN/AAltimmune Revenue ResultsActual RevenueN/AExpected Revenue$0.00 millionBeat/MissN/AYoY Revenue GrowthN/AAltimmune Announcement DetailsQuarterQ3 2025Date11/11/2025TimeBefore Market OpensConference Call DateTuesday, November 11, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Altimmune Earnings HeadlinesJohnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 PrintOctober 15 at 4:06 AM | msn.comAltimmune's (ALT) Buy Rating Reiterated at HC WainwrightOctober 13 at 2:13 AM | americanbankingnews.comQuiet Tickers. Strong Signals. Here’s What’s Brewing…The final stretch of the year is packed with uncertainty — but while others guess, smart traders focus on verified market activity. Our free Small-Cap Signals Guide shows how to spot early momentum shifts, identify small caps with breakout potential, and understand the setups analysts are watching now.October 16 at 2:00 AM | Market Crux (Ad)HC Wainwright & Co. Reiterates Altimmune (ALT) Buy RecommendationOctober 10, 2025 | msn.comAltimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Hold" by BrokeragesOctober 9, 2025 | americanbankingnews.comALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmOctober 8, 2025 | globenewswire.comSee More Altimmune Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Altimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Altimmune and other key companies, straight to your email. Email Address About AltimmuneAltimmune (NASDAQ:ALT) is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions. Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose. This candidate is being advanced in collaboration with the University of Alabama at Birmingham and is supported by the National Institute of Allergy and Infectious Diseases. In parallel, Altimmune’s HepTcell program aims to treat chronic hepatitis B by eliciting targeted T-cell responses capable of clearing infected liver cells. Altimmune’s AdCOVID™ platform uses a replication-incompetent adenovirus vector to deliver vaccine antigens directly to the nasal mucosa, and it is also under evaluation for additional respiratory pathogens, including coronaviruses. The company maintains a pipeline of preclinical programs in liver and metabolic diseases, reflecting its commitment to harnessing immunotherapy and vaccine design across multiple therapeutic areas. The company’s leadership team combines extensive scientific expertise and operational experience in vaccine research and development. Through a strategic blend of translational science and external partnerships, Altimmune seeks to advance innovative therapies that improve patient outcomes and address global health challenges.View Altimmune ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings HDFC Bank (10/17/2025)Truist Financial (10/17/2025)American Express (10/17/2025)Nasdaq (10/21/2025)Texas Instruments (10/21/2025)Intuitive Surgical (10/21/2025)Netflix (10/21/2025)Verizon Communications (10/21/2025)General Motors (10/21/2025)CocaCola (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
